Sildigra CT

Product Description

Sildigra CT is a pharmaceutical formulation containing Sildenafil as its active component, classified as a phosphodiesterase type 5 (PDE5) inhibitor. This therapeutic agent is specifically developed to manage male erectile dysfunction (ED).

Uses

Sildigra CT is indicated for the treatment of erectile dysfunction, a prevalent medical condition that impacts sexual performance. This disorder manifests when a male experiences difficulty achieving or sustaining an erection sufficient for satisfactory sexual activity.

How to Use

This medication should be administered orally, typically 60 minutes prior to anticipated sexual intercourse. While Sildigra CT may be consumed with or without food, ingestion alongside high-fat meals may delay its onset of action. Strict adherence to prescribed dosing is essential, with administration not exceeding once within a 24-hour timeframe.

Mechanism of Action

Sildigra CT exerts its therapeutic effect by selectively inhibiting the PDE5 enzyme. This inhibition prevents the degradation of cyclic guanosine monophosphate (cGMP), a crucial mediator that promotes penile vascular relaxation and subsequent blood flow enhancement during sexual stimulation. PDE5 blockade results in elevated cGMP levels, thereby facilitating the physiological erectile response.

Benefits

The principal advantage of Sildigra CT lies in its capacity to restore sexual function, effectively treating erectile dysfunction while simultaneously improving self-assurance and alleviating psychological distress associated with this condition.

Common Adverse Effects

Frequently reported side effects include cephalalgia, facial flushing, gastrointestinal discomfort, visual disturbances, rhinitis, dorsalgia, myalgia, nausea, and vertigo. While typically transient in nature, persistent symptoms warrant immediate medical consultation.

Dosage and Administration

The conventional dosage regimen consists of one tablet administered daily, approximately 60 minutes preceding sexual activity. Dosage adjustments may be implemented based on individual therapeutic response and tolerability. Optimal outcomes are achieved through strict compliance with medical directives.

Precautions

Sildigra CT is contraindicated in patients with severe cardiovascular pathologies, hepatic or renal impairment, hematological disorders, or concurrent nitrate therapy. Concomitant use with other PDE5 inhibitors is strictly prohibited.

Storage

Maintain Sildigra CT in a temperature-controlled environment protected from moisture and direct sunlight. Ensure secure storage inaccessible to minors and domestic animals.